Infiltrating T-lymphocyte receptor Vβ gene family utilazation in autoimmune thyroid disease

Journal of International Medical Research

Volumn 34, Issue 6, 2006, Pages 585-595

  Zhang, J ^a   Zhang, M ^a   Wang, Y ^a   Shi, B ^a   Zhu, B ^a   Si, L ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Graves disease; Hashimoto's disease; T cell receptor; V gene family

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; LYMPHOCYTE RECEPTOR; LYMPHOCYTE RECEPTOR VBETA; LYMPHOCYTE RECEPTOR VBETA3; LYMPHOCYTE RECEPTOR VBETA5; LYMPHOCYTE RECEPTOR VBETA8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TARGETING; RNA EXTRACTION;

EID: 33846526145     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400603     Document Type: Article

References (32)

1. Offner H, Vandenbark AA: T cell receptor V genes in multiple sclerosis: increased use of TCR Vβ8 and TCR Vβ5 in MBP-specific clones. Int Rev Immunol 1999; 18: 9-36.
2. Simone E, Daniel D, Schloot N, Gottlieb P, Babu S, Kawasaki E, et al: T cell receptor restriction of diabetogenic autoimmune NOD T cell. Proc Natl Acad Sci USA 1997; 94: 2518-2521.
3. Illes Z, Shimamura M, Newcombe J, Oka N, Yamamura T: Accumulation of V(alpha) 7.2-J(Alpha)33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 2004; 16: 223-230.
4. Kumar V: Homeostatic control of immunity by TCR peptide-specific Tregs. J Clin Invest 2004; 114: 1222-1226.
5. Matsumoto Y: new approach to immunotherapy against organ-specific autoimmune disease with T cell receptor and chemokine receptor DNA vaccine. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 73-77.
6. Binz H, Frischknecht H, Shen FW: Idiotypic deteminants on T-cell populations. J Exp Med 1979; 149: 910-922.
7. Vandenbark AA, Hashim G, Offner H: Immunization with a synthetic T-cell receptor V-region peptide protects against experiment auto-immune encephalomyelitis. Nature 1989; 341: 541-544.
8. Ben-Yehuda A, Bar-Tana R, Livoff A, Ron N, Cohen IR, Naparstek Y: Lymph node cell vaccination against the lupus syndrome of MRL/lpr/lpr mice. Lupus 1996; 5: 232-236.
9. Elias D, Tikochinski, Frankel G, Cohen IR: Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide. Int Immunol 1999; 11: 957-966.
10. Zhang J: T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev Vaccines 2002; 1: 285-292.
11. Van der Aa A, Helling N, Medear R, Gelin G, Palmers Y, Raus J, et al: T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 2003; 131: 155-168.
12. Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, et al: T cell receptor peptide vaccination in rheumatoid arthritis: a placebo controlled trial using a combination of Vβ2, Vβ4, Vβ17 peptides. Arthritis Rheum 1998; 41: 1919-1929.
13. Bridges SL Jr, Moreland LW: T cell receptor peptide vaccination in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24: 641-650.
14. Maynard J, Petersson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, et al: Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 2005; 22: 81-92.
15. Heufelder AE, herterich S, Ernst G, Bahn RS, Scriba PC: Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinology 1995; 132: 266-277.
16. Davies TF, Concepcion ES, Ben-Nun A, Graves PN, Tarian G: T cell receptor V gene use in autoimmune thyroid disease: direct assessment by thyroid aspiration. J Clin Endocrinol Metab 1993; 76: 660-666.
17. Kozovska MF, Yamamura T, Tabira T: T-T cellular interaction between CD4-CD regulatory T cells and T cell clones presenting TCR peptide. Its implication for TCR vaccination against experimental autoimmune encephalomyelitis. J Immunol 1996; 157: 1781-1790.
18. Suzuki M, Cheng KC, Krug MS, Yoo TJ: Successful prevention of retrocochlear hearing loss in murine experimental allergic encephalomyelitis with T cell receptor Vβ8 specific antibody. Ann Otol Rhinol Laryngol 1998; 107: 917-927.
19. Stinissen P, Zhang J, Medaer R, Vandevyver C, Raus J: Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 1996; 45: 500-511.
20. Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, et al: Results of a phase I clinical trial of T cell receptor vaccine in patients with multiple sclerosis. II comparative analysis of TCR utilization in CSF T cell populations before and after vaccination with a TCR Vβ6 CDR2 peptide. J Neuroimmunol 1997; 76: 29-38.
21. Musselli C, Daverio-Zanetti S, Zanetti M: Antigenized antibodies expresing Vβ8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis. J Immune Based Ther Vaccines 2004; 2: 9-29.
22. Matsumoto Y, Jee Y, Sugisaki M: Successful TCR based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J Immunol 2000; 164: 2248-2254.
23. Kumar V, Maglione J, Thatte J, Pederson B, Sercarz E, Ward ES: Introduction of a type 1 regulatory CD4 T cell response following v beta 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int Immunol 2001; 13: 835-841.
24. Miyakoshi A, Yoon WK, Jee Y, Matsumoto Y: Characterization of the antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats. J Immunol 2003; 170: 6371-6378.
25. Wu H, Walters G, Knight JF, Alexander SI: DNA vaccination against specific pathogenic TCRs reduces proteinuria in active Heymann nephritis by inducing specific autoantibodies. J Immunol 2003; 171: 4824-4829.
26. Inoki T, Yamagami S, Sakai R, Isobe M, Tsuru T, Kawashima H: Suppression of experimental outoimmune uveoretinitis by anti-alphabeta TCR monoclonal antibody. Jpn J Ophthalmol 2002; 46: 518-524.
27. Masteller EL, Bluestone JA: Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol 2002; 14: 652-659.
28. Davies TF, Martin A, Concepcion ES, Graves P, Cohen WL, Ben-Nun A: Evidence of limited variability of antigen receptors on intrathyroidal T cells autoimmune thyroid disease. N Engl J Med 1991; 325: 238-244.
29. McIntosh RS, Watson PF, Pickerill AP, Davies R, Weetman AP: No trestriction of intrathyroidal T cell receptor Vα families in the thyroid of Graves' disease. Clin Exp Immunol 1993; 91: 147-152.
30. McMurray RW, Hoffman RW, Tang H, Braley-Mullen H: T cell receptor Vβ usage in murine experimental autoimmune thyroid. Cell Immunol 1996; 172: 1-9.
31. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G: Determinant spreading and the dynamics of the autoimmune T cell repertoire. Immunol Today 1993; 14: 203-208.
32. Navarrete C, Bottazo GF: In search of ICR restriction in autoreactivity T cell in human autoimmunity: why is it so elusive? Clin Exp Immunol 1993; 91: 189-192.